Humana Eases Investor Fears With Q3 Earnings, Approaches Future With Caution

  • Nov 01, 2024

    Humana’s third-quarter 2024 earnings results were better than many analysts feared, driven by higher-than-expected Medicare Advantage (MA) revenue and outperformance of the company’s CenterWell clinics. 

    For the quarter ending Sept. 30, Humana reported adjusted earnings per share (EPS) of $4.16, beating Wall Street’s consensus estimate of $3.42. The company’s consolidated medical loss ratio (MLR) of 89.8% was in line with the consensus estimate. During an Oct. 30 conference call to discuss quarterly earnings, CEO Jim Rechtin noted that the company slightly improved its 2024 EPS outlook from “approximately” $16.00 to “at least” $16.00. This was in sharp contrast to the company’s second-quarter release, which saw the company’s stock tumble more than 10% on the news of higher-than-anticipated inpatient admissions and the company not raising its full-year guidance. 

    Read more
    © 2024 MMIT
  • Jill Drachenberg

    Jill has been a reporter and editor since 2005, mainly focusing on business and health care. Before joining AIS Health, she was an editor for Relias Media (formerly AHC Media), focusing on topics such as case management, medical ethics, risk management, infection control, hospital management, and contraceptive technology. She has a B.A. in journalism from Georgia State University.

The Latest
Meet Our Reporters

Meet Our Reporters

×